RESEARCHER PROFILE
Frank Stephen Hodi
F
Harvard University
Frank Stephen Hodi works in Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, T-cell and B-cell Immunology. Recorded institutional associations include Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center.
1,583Publications
163,538Citations
155H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · 15,151 citationsSafety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
2012 · 12,603 citationsCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
2015 · 8,134 citationsOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5,342 citationsPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
2014 · 5,222 citationsFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · 3,703 citationsSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
2013 · 3,392 citationsGuidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 · 3,222 citationsNivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
2015 · 2,784 citationsNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
2015 · 2,676 citationsiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 · 2,464 citationsTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
2017 · 2,379 citationsSurvival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
2014 · 2,218 citationsPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 · 2,139 citationsSubsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
2019 · 2,063 citationsRECIST 1.1—Update and clarification: From the RECIST committee
2016 · 1,895 citationsAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
2014 · 1,771 citationsAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · 1,577 citationsPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
2015 · 1,572 citationsOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
2017 · 1,516 citationsA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
2018 · 1,416 citationsNivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
2018 · 1,395 citationsCombined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
2018 · 1,321 citationsProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
2016 · 1,318 citationsGenomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
2018 · 1,238 citations
